

Pediatric Dermatology at the SID

Wednesday, May 16, 2018

International Eczema Council (IEC)

Phenotype-Genotype Correlations and Personalized Medicine in Atopic Dermatitis

12:00 pm – 3:00 pm

Butler

- 12:00 pm Welcome and Overview
Emma Guttman-Yassky
- 12:05 pm Genetic Mechanism of Skin Barrier Failure in AD
Wilson Liao, MD
- 12:35 Genetic Mechanisms of Immune Dysregulation and Comorbidities in AD
Stephan Weidinger, MD/MaHM
- 1:05 pm Skin Barrier, Immune Dysregulation and Itch-Therapeutic Implications
Kenji Kabashima, MD/PhD
- 1:35 pm Differences in Immune Dysregulation in Various AD Phenotypes and the Road to Personalized Medicine
Emma Guttman-Yassky, MD/PhD
- 2:00 pm Q&A with Plenary Speakers
- 2:15 pm Abstract Presentations

Abstract #555, Integrating serum and skin biomarkers to assess disease extent beyond clinical scores, advancing precision therapeutics. Kunal Malik et al., Mount Sinai, New York, NY

Abstract #559, ASN002 a dual oral inhibitor of JAK/SYK signaling improves clinical outcomes and associated cutaneous inflammation in moderate-to-severe atopic dermatitis patients. Emma Guttman et al., Mount Sinai, New York NY

Abstract #1446, Atopic Cytokines IL4/13 Perturb iPSC-Derived Itch-Specific Sensory Neurons. Zongyou Guo et al., Columbia University, New York, NY

Abstract #1039, Skin microbiome profiles of atopic dermatitis patients segregate into two community composition types that are stable before and after therapy. John Common et al., A*STAR, Singapore

International Psoriasis Council

The Psoriatic Disease Mechanistic Scenarios

1:00 pm – 4:30 pm

St. John's 28-29

- 2:15 pm The Genetics of Pustular Psoriasis
Kazumitsu Sugiura, MD/PhD

American Acne and Rosacea Society (AARS)

7th Annual AARS Scientific Symposium

1:00 pm – 4:00 pm

St. John's 22-23

- 1:00 pm Welcome and AARS Announcements
Diane Thiboutot, MD, AARS
- 1:15 pm Abstract #051, Antimicrobial Activity of Cytolytic Th17 Cells Targeting Propionibacterium Acnes.
George Agak, PhD
- 1:30 pm Abstract #1023, Distinct C. Acnes Strains Isolated from Lesional and Non-Lesional Regions of Acne Promote Differential Immune Responses.
Alan O'Neill, PhD
- 1:45 pm Abstract #992, The Acne Microbiome Response to Isotretinoin Therapy.
William H. McCoy, IV, MD/PhD
- 2:00 pm Abstract #1016, Lysis by Bacteriophage Can Modulate Cutibacterium Acnes-Induced Immune Responses.
Laura Marinelli, MD
- 2:15 pm Abstract #1279, An In Vivo Model for Post-Inflammatory Hyperpigmentation.
Taylor Braunberger, MD
- 2:30 pm Abstract #1040, P. Acnes Carbohydrates from Acne-Associated Phylotypes Induce Distinct Inflammatory Response in Comparison to Carbohydrates from Healthy Phylotypes: A Potential Ligand Implicated in Acne Disease Pathogenesis.
Evyatar Evron, PhD
- 2:45 pm Abstract #1318, Both Lesional and Non-Lesional Skin from Acne Patients Shows Robust IL-17 Skewing and Upregulation of Antimicrobial Peptides.
Ning Zhang, PhD
- 3:00 pm Abstract #240, Frequency of acne in lactose intolerant patients: A Cross-Sectional Study within a Large US Patient Population.
Kelsey Orrell, MD

Opening Ceremonies

5:00 pm – 5:30 pm

Gatlin D-E

Rising Stars Lectures

5:30 pm – 6:30 pm

Gatlin D-E

- 5:30 pm SID Guest Lecture
Sexual Dimorphism in Autoimmunity
Johann Gudjonsson, MD/PhD

- 5:50 pm JSID Guest Lecture
Skin Research Provides a Window into New Aspects of Systemic Disease
Pathogenesis
Yoshihide Asano, MD/PhD
- 6:10 pm ESDR Guest Lecture
The Aged Skin Microenvironment
Amaya Viros, MD/PhD
-

Thursday, May 17, 2018

Promoting Diversity and Inclusion: A Conversation for Trainees and Leadership

7:00 am-8:30 am

Panzacola G-1

- 7:00 am What is the SID doing to promote Diversity and Inclusion?
Russell P. Hall, MD and Nicole Ward, PhD
- 7:10 am Introduction of Keynote Speaker Robyn Klein, MD, PhD
Lynn Cornelius, MD
- 7:15 am Speaking Out About Gender Imbalance in Invited Speakers Improves Diversity
Robyn Klein, MD, PhD
- 7:35 am Q&A
- 7:40 am Introduction of Panel Format and Panel Members
- 7:45 am Panel Discussion of Pre-Authorized Questions
- 8:10 am Introduction of SID Toolkit for Diversity and Inclusion
Valerie Horseley, PhD
- 8:25 am Closing Remarks
Nicole Ward, PhD

Medical Dermatology Society (MDS)

7:00 am-8:30 am

Conway

- 8:04 am Abstract #502, Impact of Cyclosporine in the management of SJS/TEN.
Radhika Shah, PharmD
- 8:16 am Abstract #1280, The role of surgery in hidradenitis suppurativa management.
Charles Puza, MD

Plenary Session I

8:45 am – 9:45 am

Gatlin D-E

- 8:45 am Abstract #071, Human central memory T cells generate superior numbers of resident memory T cells in skin.
T. Matos, A. Gehad, J. Teague, B. Dyring-Andersen, C. Yang, J. OMalley, R. Watanabe, T. Kupper and R. Clark.
- 8:57 am Abstract #013, Cholesterol 25-hydroxylase expressing CD4+ T cell regulates skin inflammation.
H. Takahashi, H. Nomura, H. Iriki, A. Kubo, M. Mukai, T. Sasaki, Y. Mikami, J. O'Shea and M. Amagai.
- 9:09 am Abstract #1225, Paving the road to explain melanocyte loss in vitiligo: An uncovered role of matrix metalloprotease MMP9.
N. Boukhedouni, C. Martins, A. Darrigade, C. Barrault, J. Garnier, J. Rambert, A. Taieb, F. Bernard, J. Seneschal and K. Boniface.
- 9:21 am Abstract #848, Blockade of CX3CL1-CX3CR1 pathway attenuates skin inflammation, fibrosis, and vascular injury in experimental mouse models of systemic sclerosis.
L. Vu Huy, T. Chino, N. Oyama, T. Matsushita, T. Obara, Y. Kuboi, N. Ishii, A. Machinaga, H. Ogasawara, W. Ikeda, T. Imai and M. Hasegawa.
- 9:33 am Abstract #426, Clinical improvement in atopic dermatitis following autologous application of microbiome therapy targeting Staphylococcus aureus.
T. Nakatsuji, T. Yun, A. Butcher, A. Hayashi, K. Chun, F. Shafiq, J. Kim, L. Zaramela, K. Zengler, T. Hata and RL. Gallo.

SID Herman Beerman Lecture

9:45 am – 10:15 am

Gatlin D-E

The Skin Microbiome: At the Interface between Human and Environmental Microbiomes
Rob Knight, PhD

Plenary Session II

10:15 am – 11:15 am

Gatlin D-E

- 10:15 am Abstract #1240, Endovascular progenitors initiate and drive de novo vascularisation in melanoma.
J. Patel, J. Dight, P. Donovan, H. Wong and K. Khosrotehrani.

- 10:27 am Abstract #1338, Dermal Wnt/ β -catenin activation tunably controls hair follicle initiation.
K. Gupta, D. Chen, J. Levinsohn, K. Choate, M. Taketo and P. Myung.
- 10:39 am Abstract #1362, The role of Fgf20 in establishing the hair follicle dermal condensate.
LC. Biggs, OJM. Mäkelä, S. Myllymäki, R. Das Roy, K. Närhi and ML. Mikkola.
- 10:51 am Abstract #538, FcRn blockade with SYNT001 for the treatment of pemphigus.
VP. Werth, D. Culton, L. Blumberg, J. Humphries, R. Blumberg and R. Hall.
- 11:03 am Abstract #624, KMT2D epigenetically regulates p63 target enhancers to coordinate epithelial homeostasis.
E. Lin-Shiao, Y. Lan, A. Anderson, C. Simpson, R. Saffie, G. Donahue, P. Sen, L. Busino, BA. Garcia, S. Berger and B. Capell.

Come See My Poster Session I

11:15 am – 11:30 am

Gatlin D-E

- 11:26 am Abstract #798, Biallelic COL7A1 editing in iPSCs via CRISPR/Cas9 for recessive dystrophic epidermolysis bullosa mutations.
J. Jackow, Z. Guo, H. Abaci, Y. Doucet, J. Shin, C. Hansen, J. Salas and A. Christiano.

Aclaris Therapeutics Symposium

JAK ‘Be Nimble’: New Applications of JAK Inhibitors in Dermatology

12:00 pm – 1:30 pm

Gatlin D-E

- 12:05 pm JAK Inhibitors 101
Paul Changelian, PhD
- 12:20 pm Abstract #503, Tofacitinib for recalcitrant cutaneous dermatomyositis.
Abeer Alsarheed
- Abstract #102, CXCL9 drives morphea pathogenesis in mice.
Druhmi Patel
- Abstract #1311, Efficacy of topical tofacitinib in promoting hair growth in non-scarring alopecia.
Jindapa Thummakriengkrai

Selected ePoster Discussions I

Clinical Research: Epidemiology of Skin Diseases

12:15 pm – 1:15 pm

Gatlin Foyer Kiosk #2

12:27 pm Abstract #383, Doxycycline effects on the gut and skin microbiomes and lipidome in acne.

K. Haas, M. Notay, W. Rodriguez, M. Rolston, A. Clark, W. Burney, J. Newman, T. Pedersen, R. Crawford, S. Dandekar and R. Sivamani.

1:09 pm Abstract #285, Disparities in outpatient dermatologic health care access and utilization in the United States.

R. Tripathi, KD. Knusel and JS. Bordeaux.

Selected ePoster Discussions I

Epithelial Biology

12:15 pm – 1:15 pm

Gatlin Foyer Kiosk #3

12:21 pm Abstract #798, Biallelic COL7A1 editing in iPSCs via CRISPR/Cas9 for recessive dystrophic epidermolysis bullosa mutations.

J. Jackow, Z. Guo, H. Abaci, Y. Doucet, J. Shin, C. Hansen, J. Salas and A. Christiano.

12:45 pm Abstract #824, Functional genomic analysis of the IL2RA susceptibility region in alopecia areata.

A. Abdelaziz, S. Erjavec, L. Petukhova, S. Gelfman, I. Ionita-Laza and AM. Christiano.

Selected ePoster Discussions I

Skin of Color

12:15 pm – 1:15 pm

Gatlin Foyer Kiosk #5

12:33 pm Abstract #1283, Somatic GNAQ mutation in different structures of Port-wine Macrocheilia.

G. Ma, F. Liu, R. Cai, Y. Liu and X. Lin.

1:03 pm Abstract #1290, Despite abnormal vitamin D receptor expression in keloid scars, keloid keratinocytes can respond to vitamin D treatment in vitro.

DM. Supp and JM. Hahn.

Selected ePoster Discussions I

Tissue Regeneration and Wound Healing

12:15 pm – 1:15 pm

Gatlin Foyer Kiosk #6

12:27 pm Abstract #1446, Atopic cytokines IL4/13 perturb iPSC-derived itch-specific sensory neurons.

Z. Guo, C. Tong, Y. Doucet, H. Abaci, J. Jackow, W. Zeng, C. Hansen, E. Lumpkin and A. Christiano.

ESDR Rudi Cormane Lecture

2:00 pm – 2:30 pm

Gatlin D-E

Above and Beyond: New Frontiers in Cutaneous Immunology
Tilo Biedermann, MD

JSID Tanioku Kihei Memorial Lecture

2:30 pm – 3:00 pm

Gatlin D-E

Environment and Skin
Jean Krutmann, MD

Concurrent Mini-Symposium 2

Clinical Research: Epidemiology of Skin Diseases

3:15 pm – 5:45 pm

Ponzacola F-1/2

3:27 pm Abstract #247, Patterns of atopic eczema activity in childhood and adulthood: Results from 2 national prospective British cohort studies.
M. Ye, Y. Yew, SM. Langan and K. Abuabara.

3:39 pm Abstract #290, Histological subtype and anatomical location in pediatric malignant melanoma (MM): A population-based study from the surveillance, epidemiology, and end results (SEER) program.
RC. Kelm, Y. Ali, KA. Orrell, SM. Rangel, LL. Kruse, A. Wagner, P. Gerami, DP. West and B. Nardone.

5:27 pm Abstract #278, Risk of myocardial infarctions is increased in patients with neurofibromatosis type 1.
S. Peltonen, R. Kallionpää, H. Ylä-Outinen and J. Peltonen.

Concurrent Mini-Symposium 3

Innate Immunity, Microbiology, Inflammation

3:15 pm – 5:45 pm

Gatlin D-E

5:03 pm Abstract #927, Peripheral nerves are involved in the development of Staphylococcus aureus-induced skin inflammation possibly via recruiting basophils.
C. Nakashima, A. Otsuka and K. Kabashima.

Concurrent Mini-Symposium 4

Skin of Color

3:15 pm – 5:45 pm

Conway

3:15 pm Abstract #1274, The potential of patient iPSC-derived melanocytes in vitiligo therapy.
L. Liu and Y. Li.

3:39 pm Abstract #1276, Oxidative stress induced melanocytes release of HMGB1 is critical for keratinocyte production of proinflammatory cytokines in vitiligo.

T. Cui, P. Song, W. Zhang, S. Li, X. Yi, Z. Jian, L. Liu, T. Gao and C. Li.

- 3:51 pm Abstract #1285, Atopic dermatitis in African American patients is TH2/TH22-driven with TH1/TH17 attenuation and downregulation of loricrin.
RD. Sanyal, AB. Pavel, TC. Chan, X. Zheng, J. Glickman and E. Guttman-Yassky.
- 4:15 pm Abstract #1292, Comparative study of the immunological profile in stable segmental and non segmental vitiligo patients undergoing melanocyte keratinocyte transplantation.
MA. Refat, JP. Strassner, ML. Frisoli, M. Rashighi, E. Nada, R. Saleh, M. Ali, B. Mahmoud, D. Goldberg and JE. Harris.
- 4:27 pm Abstract #724, Recent and independent emergences of population-specific enhancer eQTLs that modulate Involucrin gene expression for human skin barrier calibration.
E. Brettmann, Z. Goodwin, A. Quiggle and C. de Guzman Strong.

Concurrent Mini-Symposium 5
Tissue Regeneration and Wound Healing
3:15 pm – 5:45 pm

Panzacola G-1

- 4:27 pm Abstract #1465, Optimization/characterization of a Focal Dermal Hypoplasia mouse model to test potential treatments.
D. Chiluiza, P. Hsieh and S. Divito.

New Frontiers and Pivotal Investigation-Based Advances in the Pathoimmunobiology and Management of Atopic Dermatitis
6:00 pm – 7:30 pm

Panzacola F-3/4

- 6:00 pm The Translational Path for a Cytokine-Targeting Therapeutic Approach in Atopic Dermatitis
Emma Guttman-Yassky, MD/PhD
- 6:20 am The Disease Burden, Quality-of-Life Impairment, and Comorbidities of AD and The Implications for Treatment for Patients with Moderate-to-Severe Disease
Jonathan I. Silverberg, MD/PhD/MPH
- 6:40 pm The Therapeutic Landscape of Atopic Dermatitis: Th2 Targeting and Beyond
Eric Simpson, MD
- 7:00 pm Bringing the Pathogenic Advances and Novel Treatments to Children with AD: What have we Learned?
Amy S. Paller, MD/MSci

7:20 pm The Disease Burden, Quality-of-Life Impairment, and Comorbidities of AD and Implications for Treatment for Patients with Moderate-to-Severe Disease— A Year 2018 Investigation-to-Application Update
Emma Guttman-Yassky, MD/PhD

Friday, May 18, 2018

The Pediatric Dermatology Research Alliance (PeDRA)/Society for Pediatric Dermatology (SPD)

7:00 am – 8:30 am

Conway

- 7:00 am Welcome
Yvonne Chiu, MD and Amy Paller, MD
- 7:05 am Pediatric Dermatology Roadmap
Yvonne Chiu, MD
- 7:20 am Novel Approaches to Treat Recessive Dystrophic Epidermolysis Bullosa
Leena Bruckner-Tuderman, MD
- 7:50 am Abstract #719, Abnormalities in skin barrier status correlate with autism in a murine model: could assessments of skin barrier function assist in early diagnosis of autism?
Peter Elias, MD, et al.
- 8:00 am Abstract #648, The barrier abnormality of early-onset pediatric atopic dermatitis results from abnormalities in tight junctions and epidermal lipids, but not differentiation proteins.
Patrick Brunner, MD, et al.
- 8:10 am Abstract #766, The phenotypic spectrum of vascular anomalies associated with postzygotic mosaic variants in G-proteins.
Shoshanna Blumenthal, et al.
- 8:20 am Abstract #775, A new phenotype combining hidradenitis suppurativa with Dowling-Degos disease caused by a founder mutation in PSENEN.
Mor Pavlovsky, MD, et al.

ESDR Guest Lecture

8:45 am – 9:15 am

Gatlin D-E

Fluorescence Microscopy: The Resolution Revolution
Nobel Laureate Stefan W. Hell, PhD

Plenary Session III

10:30 am – 11:30 am

Gatlin D-E

- 10:30 am Abstract #628, Live imaging of granular cells during cornification in the epidermal equivalent model.
S. Ipponjima, Y. Umino, M. Nagayama and M. Denda.
- 10:42 am Abstract #784, The p63 - iRHOM2 signalling axis in the keratinocyte stress response.
Chikh, P. Arcidiacono, C. Webb, M. Brooke, H. Zhou and D. Kelsell.
- 10:54 am Abstract #755, Mosaic RAS/MAPK variants cause sporadic vascular malformations which respond to targeted therapy. S. Polubothu, L. Al-Olabi, K. Dowsett, K. Andrews, P. Stadnik, R. Knox, W. Baird, M. Glover, C. Moss, A. Thomas, L. Biesecker, R. Semple, E. Patton and V. Kinsler.
- 11:06 am Abstract #1081, BIIB059, a monoclonal antibody targeting BDCA2, decreases Type I Interferon-related genes transcriptional activity in subjects with systemic lupus erythematosus (SLE) and active cutaneous LE (CLE).
VP. Werth, JF. Merola, R. Furie, TL. Reynolds, L. Stevenson, W. Wang, C. Musselli, R. Christmann, S. Hamann, X. Zhang, C. Barbey, D. Rabah and N. Franchimont.
- 11:18 am Abstract #1164, Ultraviolet radiation induced senescent cells and senescence associated secretory phenotype have key roles in the induction of immune tolerance.
S. Das, X. He and H. Xu.

Come See My Poster Session II

11:30 am – 11:45 am

Gatlin D-E

- 11:30 am Abstract #1278, Targeting IL-15 signaling with an anti-CD122 antibody durably reverses vitiligo.
JM. Richmond, JP. Strassner, L. Zapata, M. Garg, M. Rashighi, RL. Riding, MA. Refat, KI. Essien, L. Pell, P. Agarwal, N. Tsurushita, J. Tso and JE. Harris.
- 11:32 am Abstract #489, Dupilumab efficacy in atopic dermatitis in four randomized phase 3 trials (LIBERTY AD SOLO 1&2, CHROMOS, CAFE).
EL. Simpson, T. Bieber, M. de Bruin-Weller, A. Blauvelt, Z. Chen, M. Ardeleanu, B. Shumel, B. Akinlade and T. Hultsch.
- 11:41 am Abstract #444, Demethylzeylasteral inhibits the skin trafficking of CD8+ T cells in patients with vitiligo through the inactivation of IFN- γ -JAK-STAT1-CXCL10 signaling pathway in keratinocytes.
Y. Chang, W. Zhang and C. Li.

Selected ePoster Discussions II
Adaptive and Autoimmunity

12:30 pm – 1:30 pm

Gatlin Foyer Kiosk #1

- 12:30 pm Abstract #1278, Targeting IL-15 signaling with an anti-CD122 antibody durably reverses vitiligo.
JM. Richmond, JP. Strassner, L. Zapata, M. Garg, M. Rashighi, RL. Riding, MA. Refat, KI. Essien, L. Pell, P. Agarwal, N. Tsurushita, J. Tso and JE. Harris.

Selected ePoster Discussions II
Clinical Research: Pathophysiology and Therapeutics

12:30 pm – 1:30 pm

Gatlin Foyer Kiosk #2

- 12:30 pm Abstract #489, Dupilumab efficacy in atopic dermatitis in four randomized phase 3 trials (LIBERTY AD SOLO 1&2, CHROMOS, CAFE).
EL. Simpson, T. Bieber, M. de Bruin-Weller, A. Blauvelt, Z. Chen, M. Ardeleanu, B. Shumel, B. Akinlade and T. Hultsch.
- 12:42 pm Abstract #425, Optimization of gentamicin therapy for recessive dystrophic epidermolysis bullosa patients harboring nonsense mutations.
D. Woodley, J. Cogan, Y. Hou, V. Lincoln, D. Keene, M. Hirsch, N. Pironon, M. Titeux, A. Hovnanian and M. Chen.
- 1:06 pm Abstract #438, Phase 2 trial of a neurokinin-1 receptor antagonist for the treatment of chronic itch in epidermolysis bullosa patients.
A. Chiou, S. Choi, M. Barriga, Y. Dutt-Singkh, D. Solis, J. Nazaroff, I. Bailey-Healy, S. Li, M. Joing, P. Kwon and J. Tang.

Selected ePoster Discussions II
Clinical Research: II

12:30 pm – 1:30 pm

Gatlin Foyer Kiosk #3

- 12:42 pm Abstract #444, Demethylzeylasteral inhibits the skin trafficking of CD8+ T cells in patients with vitiligo through the inactivation of IFN- γ -JAK-STAT1-CXCL10 signaling pathway in keratinocytes.
Y. Chang, W. Zhang and C. Li.
- 12:54 pm Abstract #455, Molecular correlation with clinical outcomes in an open label clinical trial of oral tofacitinib in patients with alopecia areata.
A. Bitterman, A. Jabbari, J. Chen, A. de Jong, R. Clynes, J. Mackay-Wiggan and A. Christiano.

Selected ePoster Discussions II
Growth Factor, Cell Adhesion and Matrix Biology

12:30 pm – 1:30 pm

Gatlin Foyer Kiosk #4

1:00 pm Abstract #864, VE-cadherin internalization coordinates endothelial cell functions during vascular development.
C. Grimsley-Myers, C. Cadwell, R. Isaacson, J. Campos, W. Giang and AP. Kowalczyk.

1:06 pm Abstract #868, Hypoxia induced Cyr61 productions involved in the pathogenesis of infantile hemangioma.
P. Wu, Z. Yu, X. Lin and G.

Selected ePoster Discussions II
Skin Appendages and Stem Cell Biology
12:30 pm – 1:30 pm

Gatlin Foyer Kiosk #6

1:12 pm Abstract #1353, Inhibition of sebocyte HDAC activity promotes cytokine expression: An epigenetic model for acne pathogenesis by *Propionibacterium acnes*.
JA. Sanford, A. O'Neill, CC. Zouboulis and RL. Gallo.

SID William Montagna Lecture
2:15 pm – 2:45 pm

Gatlin D-E

Digging Deep: Secrets of the Dermis
Valerie Horsley, PhD

JSID Guest Lecture
2:45 pm – 3:15 pm

Gatlin D-E

Control of Immune Responses by Regulatory T Cells
Shimon Sakaguchi, MD/PhD

Concurrent Mini-Symposium 8
Clinical Research: Pathophysiology and Therapeutics
3:30 pm – 6:00 pm

Panzacola F-1/2

4:42 pm Abstract #484, Mechanisms in residual plaques in patients with an overall good response to biologics.
KM. Smith, S. Mashiko, R. Edelmayer, Y. Bi, V. Kaimal, L. Olson, S. Huang, J. Wetter, K. Salte, J. Wang, X. Li, S. Garcet, A. Kannan, S. Cao, C. Maari, E. St-Cyr Proulx, Z. Liu, J. Krueger, M. Sarfati and R. Bissonnette.

5:06 pm Abstract #487, Induction of T cell exhaustion by JAK1/3 inhibition in the treatment of alopecia areata.
Z. Dai and AM. Christiano.

Concurrent Mini-Symposium 9
Growth Factors, Cell Adhesion and Matrix Biology
3:30 pm – 6:00 pm

Conway

3:42 pm Abstract #862, Absence of collagen VII binding to thrombospondin 1 promotes activation of TGF-beta in recessive dystrophic epidermolysis bullosa.
VS. Atanasova, R. Russel, TG. Webster, P. Agarwal, S. Krishnan, J. Salas, A. Fertala and AP.

Concurrent Mini-Symposium 10
Pigmentation and Melanoma
3:30 pm – 6:00 pm

Panzacola G-1

5:42 pm Abstract #1262, HSP70iQ435A-encoding DNA repigments vitiligo lesions in Sinclair swine.
S. Henning, M. Fernandez, J. Mahon, R. Duff, F. Azarafrooz, Y. Guy, A. Salzman and C. Le Poole.

SATO Pharmaceutical CO., LTD.,
Tokyo JAPAN
SATO Scientific Forum at IID 2018
6:30 pm – 9:30 pm

Conway

Atopic Dermatitis - How our Increasing Understanding of Pathogenesis is Translating into New and Emerging Therapies
Amy S. Paller, MD/MSci

Saturday, May 19, 2018

Neuroimmunology of the Skin:
Regulation of the Nervous System by the Immune System
7:00 am – 8:30 am

Gatlin D-E

7:05 am Atopic Dermatitis: The Itch that Rashes
Sarina Elmariah, MD/PhD

7:25 am IL-4 and the Neuro-Immune Connection
Brian Kim, MD/PhD

7:45 am How the Spinal Cord Interprets and Modulates itch
Junichi Hachisuka, MD/PhD

8:05 am Connectivity Between the Immune and Nervous Systems with a Focus on Mast Cells

Ethan Lerner, MD/PhD

Plenary Session IV

8:45 am – 9:45 am

Gatlin D-E

- 8:45 am Abstract #433, Subcutaneous adipose tissue harbors a leukocyte compartment distinct from skin.
M. Brueggen, J. Strobl, G. Stary, H. Kiprof, L. French and G. Stingl.
- 8:57 am Abstract #221, BCC to SCC pathway switching during tumor evolution and the role of the primary cilium.
F. Kuonen, N. Huskey, G. Shankar, KY. Sarin and AE.
- 9:09 am Abstract #317, Features of pustular psoriasis observed in 863 patients: Clinical and genetic analysis of a multi-ethnic cohort.
S. Twelves, A. Mostafa, Z. Bata-Csörg, M. Szell, CEM. Griffiths, D. Burden, S. Choon, C. Smith, A. Navarini, J. Barker and F. Capon.
- 9:21 am Abstract #297, Deep Ackerman a novel deep learning method to develop dermatopathology diagnosis by artificial intelligence.
Y. Ota, K. Shido, K. Kojimako, K. Yamasaki, M. Nagasaki and S. Aiba.
- 9:33 am Abstract #160, Small non-coding RNAs control the MAPK/ERK pathway.
Z. Siprashvili, R. Marthappa Shenoy, L. Elcavage and P. Khavari.

JSID Awardee Lecture

9:45 am – 10:15 am

Gatlin D-E

Decrypting the Complex Barrier System of Mammalian Skin
Akiharu Kubo, MD/PhD

Plenary Session V

10:15 am – 11:15 am

Gatlin D-E

- 10:15 am Abstract #916, Skin resident innate lymphoid cells play an integral role in homeostatic regulation of sebaceous glands via TNF/Lymphotoxin receptor signaling to maintain microbial equilibrium.
T. Kobayashi, D. Kim, B. Voisin, T. Doebel, A. Truong, J. Lee, J. Jo, E. Kennedy, H. Kong and K. Nagao.
- 10:27 am Abstract #973, IKK/NF- κ B signaling in keratinocytes controls TNF-dependent necroptosis-and apoptosis-mediated skin inflammation.
S. Kumari, T. Van and M. Pasparakis.
- 10:39 am Abstract #1460, Keratinocyte-fibroblast crosstalk via extracellular vesicles reveals interplay of miRs that inhibit FGF7 signaling in diabetic foot ulcers.

I. Jozic, A. Ferreira, I. Pastar, H. Ramirez, M. Garcia-Contreras, J. McBride, R. Kirsner and M. Tomic-Canic.

10:51 am Abstract #270, Vildagliptin significantly increases the risk of bullous pemphigoid: A Finnish nationwide registry study.
O. Varpuluoma, A. Försti, J. Jokelainen, M. Turpeinen, M. Timonen, L. Huilaja and K. Tasanen.

11:03 am Abstract #997, Skin commensal bacteria drive the wound healing response by initiating pDC recruitment and activation in injured skin.
J. Di Domizio, C. Belkhodja, P. Chenuet, T. Murray, O. Demaria, C. Conrad, D. Speiser, B. Ryffel and M. Gilliet.

Come See My Poster Session III

11:15 am – 11:30 am

Gatlin D-E

11:15 am Abstract #559, ASN002 a dual oral inhibitor of JAK/SYK signaling improves clinical outcomes and associated cutaneous inflammation in moderate-to-severe atopic dermatitis patients.
E. Guttman-Yassky, AB. Pavel, T. Song, H. Kim, D. Zammit, S. Toker and N. Rao.

11:20 am Abstract #775, A new phenotype combining hidradenitis suppurativa with Dowling-Degos disease caused by a founder mutation in PSENEN.
M. Pavlovsky, O. Sarig, M. Eskin-Schwartz, N. Malchin, R. Bochner, A. Peled, J. Mohamad, Y. Hilerowicz, A. Gat, A. Hafner and E. Sprecher.

11:23 am Abstract #1125, A wearable, flexible, conformable and depth-modulated phototherapy device: Initial application in morphea.
S. Xu, H. Zhang, H. Zhao, AS. Paller, X. Zhao, J. Zhao and JA. Rogers.

Selected ePoster Discussions III

Clinical Research: Patient Outcomes Research

12:15 pm – 1:15 pm

Gatlin Foyer Kiosk #1

12:15 pm Abstract #559, ASN002 a dual oral inhibitor of JAK/SYK signaling improves clinical outcomes and associated cutaneous inflammation in moderate-to-severe atopic dermatitis patients.
E. Guttman-Yassky, AB. Pavel, T. Song, H. Kim, D. Zammit, S. Toker and N. Rao.

1:03 pm Abstract #541, Digital assessment of hidradenitis suppurativa disease activity.
A. Wiala, M. Schöllhammer, S. Singh, K. Rappersberger, H. Schnidar and C. Posch.

1:09 pm Abstract #598, Using the localized scleroderma cutaneous assessment tool to classify morphea by severity and identify clinically significant change in disease.
N. Teske and H. Jacobe. Dallas, TX. 1:09 pm,

Selected ePoster Discussions III

Genetic Disease, Gene Regulation and Gene Therapy

12:15 pm – 1:15 pm

Gatlin Foyer Kiosk #3

- 12:21 pm Abstract #736 , Intravenous allogeneic mesenchymal stromal cell therapy in adults with recessive dystrophic epidermolysis bullosa is safe, improves quality of life and reduces itch.
E. Rashidghamat, T. Kadiyirire, JE. Mellerio and J. McGrath.
- 12:27 pm Abstract #769, Filaggrin 2 deficiency causes generalized peeling of the skin.
J. Mohamad, O. Sarig, A. Peled, N. Malchin, R. Bochner, D. Vodo, T. Rabinowitz, M. Pavlovsky, S. Tiaber, M. Fried, M. Eskin-Schwartz, N. Shomron, J. Uitto, J. Koetsier, L. Godsel, K. Green, R. Bergman and E. Sprecher.
- 12:33 pm Abstract #775, A new phenotype combining hidradenitis suppurativa with Dowling-Degos disease caused by a founder mutation in PSENEN.
M. Pavlovsky, O. Sarig, M. Eskin-Schwartz, N. Malchin, R. Bochner, A. Peled, J. Mohamad, Y. Hilerowicz, A. Gat, A. Hafner and E. Sprecher.
- 12:39 pm Abstract #788, Genetic modifiers for ectopic mineralization: The paradigm of PXE.
Q. Li, D. Wang, J. Uitto and JP. Sundberg.
- 12:45 pm Abstract #794, Postzygotic dominant-negative mutations of RHOA cause a mosaic neuroectodermal syndrome.
P. Vabres, A. Sorlin, S. Kholmanskikh, Y. Duffourd, P. Kuentz, V. Carmignac, D. Bessis, W. Dobyns, S. Polubothu, F. Faravelli, V. Kinsler, L. Faivre, M. Ross and J. Rivière.
- 12:51 pm Abstract #799, Exome, genome, and cDNA sequencing reveal KDSR mutations cause two forms of ichthyosis and identify retinoids as pathogenesis-directed therapy.
L. Boyden, N. Vincent, J. Zhou, R. Hu, A. Paller, R. Lifton, S. Baserga and K. Choate.
- 12:57 pm Abstract #806, A circulus vitiosus causes loss of proteostasis in Cockayne syndrome.
M. Costel Alupeii, P. Maity, P. Ralf EBer, I. Krikki, F. Tuorto, M. Penzo, R. Parlato, A. Schelling, V. Laugel, L. Montanaro, K. Scharffetter-Kochanek and S. Iben.
- 1:03 pm Abstract #808, Ex vivo COL7A1 correction for recessive dystrophic epidermolysis bullosa using CRISPR/Cas9 and homology directed repair.
A. Izmiryan, C. Ganier, M. Bovolenta, A. Schmitt, F. Mavilio and A. Hovnanian.

1:09 pm Abstract #833, A genome-wide association study identifies novel loci associated with severe acne and implicates hair follicle development in acne molecular pathogenesis.
MA. Simpson, C. Petridis, AA. Navarini, C. Smith and J. Barker.

Selected ePoster Discussions III

Photobiology

12:15 pm – 1:15 pm

Gatlin Foyer Kiosk #6

12:15 pm Abstract #1125, A wearable, flexible, conformable and depth-modulated phototherapy device: Initial application in morphea.
S. Xu, H. Zhang, H. Zhao, AS. Paller, X. Zhao, J. Zhao and JA. Rogers.

ESDR Celgene Lecture

2:00 pm – 2:30 pm

Gatlin D-E

Molecules and Mechanisms of Body-Surface Surveillance by Local T cells
Adrian Hayday, PhD

SID Albert M. Kligman/Phillip Frost Leadership Lecture

2:30 pm – 3:00 pm

Gatlin D-E

Decoding the Regulatory Genome
Paul Khavari, MD/PhD

Concurrent Mini-Symposium 13

Clinical Research: Patient Outcomes Research

3:15 pm – 5:45 pm

Panzacola F-3/4

3:15 pm Abstract #591, A phase 1/2 study of genetically-corrected, collagen VII expressing autologous human dermal fibroblasts injected into the skin of patients with recessive dystrophic epidermolysis bullosa (RDEB).
M. Marinkovich, A. Lane, K. Sridhar, D. Keene, A. Malyala and J. Maslowski.

3:39 pm Abstract #517, Effects of the oral janus kinase 1 (JAK1) inhibitor PF-04965842 on patient-reported outcomes (PROs) in adults with moderate to severe atopic dermatitis (AD).
E. Simpson, A. Wollenberg, R. Bissonnette, J. Silverberg, J. Papacharalambous, L. Zhu, W. Zhang, J. Beebe, M. Vincent, E. Peeva, A. Bushmakina, J. Cappelleri and L. Chen.

4:03 pm Abstract #610, Secukinumab for patients with moderate-to-severe hidradenitis suppurativa.
L. Prussick, B. Rothstein, D. Joshipura, A. Saraiya, Y. Turkowski, A. Alomran, M. Abudu, P. Zancanaro, C. Kachuk, N. Dumont, A. Gottlieb and D. Rosmarin.

4:27 pm Abstract #524, Cultured epidermal autograft from clinically revertant skin in recessive dystrophic epidermolysis bullosa.
Y. Fujita, W. Matsumura, S. Shinkuma, S. Takashima, S. Suzuki, T. Nomura, H. Nakamura, M. Inoie and H. Shimizu.

Concurrent Mini-Symposium 15

Genetic Disease, Gene Regulation and Gene Therapy

3:15 pm – 5:45 pm

Panzacola F-1/2

3:15 pm Abstract #832 , Mechanisms of spontaneous genetic reversion in ichthyosis with confetti.

Y. Lim, Y. Lu, H. Mirza, J. Zhou, R. Hu and K. Choate.

3:27 pm Abstract #781, SMARCAD1 haploinsufficiency underlies Huriez Syndrome and associated skin cancer susceptibility.

C. Günther, M. Lee-Kirsch, J. Eckhard, A. Matanovic, F. Rüschemdorf, B. Klein, J. Esparza-Gordillo, H. Traupe, E. Delaporte and Y. Lee.

3:39 pm Abstract #734, Efficient reframed gene therapy for recessive dystrophic epidermolysis bullosa using CRISPR/Cas9.

S. Takashima, S. Shinkuma, Y. Fujita, T. Nomura, H. Nakamura and H. Shimizu.

3:51 pm Abstract #752, Simultaneous gene-editing and reprogramming of epidermolysis bullosa simplex fibroblasts.

M. Pavlova, PS. McGrath, KC. Butterfield, DR. Roop, G. Bilousova and I. Kogut.

4:03 pm Abstract #761, Topically-delivered gene suppressing nanoconstruct targets IL-17RA for psoriasis.

H. Liu, R. Kang, K. Bagnowski, J. Yu, X. Cheng, S. Radecki, W. Daniel, D. Giljohann and AS. Paller.

4:15 pm Abstract #770, An exceptional mutation in ALX4 results in ectodermal defects.

R. Bochner, M. Eskin-Schwartz, O. Sarig, A. Peled, J. Mohamad, N. Malchin, O. Isakov, G. Fainberg, N. Shomron, M. Bertolini, R. Paus and E. Sprecher.

4:27 pm Abstract #774, Focal facial dermal dysplasia type I caused by a duplication on 1p36.22.

O. Sarig, A. Hafner, N. Malchin, I. Keydar, S. Fishilevich, O. Isakov, G. Fainberg, L. Samuelov, J. Nousbeck, J. Mohamad, S. Tiaber, T. Rabinowitz, N. Shomron, D. Lancet, G. Ast and E. Sprecher.

4:39 pm Abstract #795, Decoding regulatory sequence across skin differentiation with deep learning.

D. Kim, V. Risca, J. Chappell, M. Shi, Z. Zhao, N. Jung, H. Chang, M. Snyder, W. Greenleaf, A. Kundaje and P. Khavari.

- 4:51 pm Abstract #829, The EDC enhancer 923 is required for *Ivl*, *Smcp*, and *Lce6a* gene expression and chromatin accessibility.
M. Mathyer, I. Oh, S. Matkovich, Z. Goodwin, R. Lewis and C. de Guzman
- 5:03 pm Abstract #733, Identification and molecular characterization of a CDC20 mutation in a novel mosaic variegated aneuploidy syndrome with premature aging phenotypes.
H. Fujita, T. Sasaki, T. Miyamoto, T. Mori, K. Nakabayashi, K. Hata, S. Matsuura, Y. Matsubara, M. Amagai and A. Kubo.
- 5:15 pm Abstract #762 , Stem cell origin and spatio-temporal loss of heterozygosity give rise to different types of NF1-associated neurofibroma.
Z. Chen and L. Le.
- 5:27 pm Abstract #787, Generation and characterization of a mutant rat with targeted ablation in *Samd9*, the gene responsible for normophosphatemic familial tumoral calcinosis.
J. Huang, D. Wang, E. Sprecher, JP. Sundberg, J. Uitto and Q. Li.

Concurrent Mini-Symposium 16
Pharmacology and Drug Development
3:15 pm – 5:45 pm

Conway

- 3:15 pm Abstract #1054, Sirolimus gel treatment for tuberous sclerosis complex involving facial angiofibromas and cephalic plaques: A multicenter randomized controlled trial.
M. Wataya-Kaneda, Y. Ohno, Y. Fujita, H. Yokozeki, H. Niizeki, M. Ogai, K. Fukai, H. Nagai, Y. Yoshida, I. Hamada, T. Hio, K. Shimizu and H. Murota.
- 3:27 pm Abstract #1071, Age-specific changes in the atopic dermatitis molecular phenotype.
L. Zhou, A. Raja, K. Malik, AB. Pavel, J. Glickman and E. Guttman-Yassky.
- 4:15 pm Abstract #1072, Promotion of hair growth in normal mouse skin and alopecia areata by topical treatment of HDAC inhibitors.
E. Wang, E. Wang, J. Chen and A. Christiano.
- 5:27 pm Abstract #1098, Efficacy of selective next-generation JAK inhibitors in the treatment of alopecia areata.
Z. Dai, W. Zeng and AM. Christiano.

Concurrent Mini-Symposium 18
Interdisciplinary Spotlight: Atopic Dermatitis
3:15 pm – 5:45 pm

Panzacola G-2

- 3:15 pm Abstract #404, Genetic variants in TLR1, TIRAP and PSAPL1 are enriched in a specific subgroup of adult atopic dermatitis showing persistent skin manifestation on the face and neck area.
F. Yasuda-Sekiguchi, A. Shiohama, H. Kawasaki, T. Ebihara, A. Kubo, M. Amagai and T. Sasaki.
- 3:27 pm Abstract #453, GBR 830 induces progressive and sustained changes in atopic dermatitis biomarkers in patient skin lesions.
E. Guttman-Yassky, AB. Pavel, Y. Estrada, L. Zhou, Y. Salhi, G. Gudi, V C A, J. Macoin, J. Back, F. Grossman and G. Wolff.
- 3:39 pm Abstract #434, Baseline IL-22 expression in atopic dermatitis patients stratifies therapeutic responses to fezakinumab.
A. Pavel, PM. Brunner, S. Khattri, K. Malik, J. Fuentes-Duculan, S. Garcet, MG. Lebwohl, JG. Krueger and E. Guttman-Yassky.
- 3:51 pm Abstract #554, The Janus kinase 1 (JAK1) inhibitor PF-04965842 reduces signs and symptoms of moderate to severe atopic dermatitis (AD).
M. Gooderham, S. Forman, R. Bissonnette, J. Beebe, W. Zhang, C. Banfield, L. Zhu, J. Papacharalambus, M. Vincent and E. Peeva.
- 4:03 pm Abstract #657, Characterisation of a novel murine model of atopic dermatitis.
L. Smith, S. Gatault, L. Casals-Diaz, C. Métais, M. Champion, S. Coughlin, G. Eissner and M. Steinhoff.
- 4:15 pm Abstract #650, Suprabasin-deficient mice show limited but discernible defective barrier in both skin and upper digestive tract.
S. Nakazawa, M. Aoshima, A. Funakoshi, T. Shimauchi, S. Asakawa, N. Hirasawa and Y. Tokura.
- 4:27 pm Abstract #633, Intrinsic homeostatic mechanism of stratum corneum regulated by pH.
Y. Furuichi, T. Matsui, H. Kawasaki and M. Amagai.
- 4:39 pm Abstract #1295, Discovery of filaggrin loss-of-function mutations R788X in Hispanic and S3640X in African-American/Native American children with atopic dermatitis.
M. Mathyer, A. Quiggle, CX. Wong, SL. Denil, M. Kumar, H. Ciliberto, K. Ramsey, S. Bayliss, A. Paller, JE. Common and C. de Guzman Strong.
- 4:51 pm Abstract #234 , Altered patterns of growth in infants with atopic eczema commence in-utero.
S. El-Heis, S. Crozier, E. Healy and K. Godfrey.
- 5:03 pm Abstract #264, Atopic dermatitis is associated with fragile homes in US children.
C. McKenzie and JI. Silverberg.

- 5:15 pm Abstract #920, Quorum sensing between bacterial species on skin protects against barrier disruption and inflammation promoted by *Staphylococcus aureus*.
MR. Williams, JA. Sanford, T. Nakatsuji, AR. Horswill and R.L Gallo.
- 5:27 pm Abstract #1066, Biomarkers CCL17/TARC and total IgE do not predict clinical response to dupilumab in atopic dermatitis (AD): A post hoc analysis of pooled phase 3 data (SOLO 1 & 2).
JD. Hamilton, Z. Chen, LA. Beck, EL. Simpson, T. Hultsch, NMH. Graham, G. Pirozzi, M. Ruddy and M. Ardeleanu.

Closing Ceremonies

6:00 pm – 6:30 pm

Gatlin D-E

Posters

Abstract Number	Title
008	An exploration of the histological features of dermatomyositis
015	Indirect comparison of ixekizumab versus guselkumab up to week 12
022	Distinct transcriptome signature of skin-resident memory T cells and migratory memory T cells in atopic dermatitis
027	Myelin basic protein antibodies as a biomarker in morphea
031	IgG from atopic dermatitis patients induces IL-17 and IL-10 production in infant intra-thymic TCD4 and TCD8 cells
036	Keratinocyte-derived IL-15 links oxidative stress to melanocytes immunologic destruction in vitiligo
051	Antimicrobial activity of cytolytic Th17 cells targeting <i>Propionibacterium acnes</i>
052	Vitiligo is characterized by multi-axis T-cell activation in blood
067	Highly functional Skin NKG2D+ CD8+ Effector Memory T cells in vitiligo
069	Nanoparticle induced immunomodulation in a model of allergic contact dermatitis
098	Distinct chemokine signals promote T regulatory cell and T effector cell migration to the skin during vitiligo
102	CXCL9 drives morphea pathogenesis in mice
115	Using Machine Learning to Predict the Occurrence of Psoriatic Arthritis in the Kaiser Permanente GERA Cohort
127	NDRG1 regulates proliferation of endothelial cells of infantile hemangioma
137	Mixed phenotype acute leukemia in xeroderma pigmentosum
141	Potential consequences of the interaction of squamous cell carcinoma cells with EDA fibronectin in recessive dystrophic epidermolysis bullosa
224	Mechanisms of squamous cell carcinoma development in patients with recessive dystrophic epidermolysis bullosa
235	Accountable Care Organization webpages: Another stumbling block for Medicaid

	patients seeking dermatologic care
240	Frequency of acne in lactose intolerant patients: A cross-sectional study within a large US patient population
245	Sleep disturbances in children with atopic dermatitis throughout childhood: A population-based longitudinal birth cohort study
252	Comparison of psychological distress between psoriasis patients on biologic versus oral therapies: An epidemiologic study of moderate-to-severe psoriasis patients in the U.S.
254	The sun protective behaviors and attitudes of early childhood programs in Illinois
257	Cutaneous tumors in tuberous sclerosis complex correlate with pulmonary disease severity
258	National Survey of Quality of Life and Disease Severity in Patients with Congenital Ichthyosis
259	Uncommon filaggrin variants are associated with persistent atopic dermatitis in African-Americans
263	Incidence and survival of pediatric soft tissue tumors of the skin and subcutaneous tissue
265	Osteopenia is common in mild forms of epidermolysis bullosa
269	Genetic ancestry does not influence atopic dermatitis susceptibility or disease activity among African Americans
271	Psoriasis patients' perceptions of therapies differ by race
274	Prevalence and relative risk of microscopic colitis and chronic diarrhea in dermatomyositis
275	Epidemiology of antibiotic prescribing in Dermatology: A retrospective analysis 2008-2016
276	Systematic review of autoimmune comorbidities in vitiligo
283	Molecular epidemiology of non-syndromic autosomal recessive congenital ichthyosis in a middle eastern population
285	Disparities in outpatient dermatologic health care access and utilization in the United States
286	Chilblain lupus erythematosus - clinical and histologic characterization of an institutional cohort
287	Impact of skin infections on medical expenditures in patients with atopic dermatitis
288	Pain burden in atopic dermatitis
306	Racial disparities in medical visits among children with atopic dermatitis in the Pediatric Eczema Elective Registry
319	Racial characteristics of Alopecia Areata in the US from the National Alopecia Areata Registry
328	50% wound healing correlates with RDEB patient reported outcomes in pain, itch and skin durability
334	The sun and your health: Targeting teenagers and adolescents in British Columbia
336	Characterization of oral antibiotics for acne treatment
337	Body site distribution of pediatric-onset morphea
355	Clinical diagnosis and role of molecular techniques in diagnosis of encephalocraniocutaneous lipomatosis

358	Plantar distribution of hand-foot skin reaction related to use of a multikinase inhibitor and hard orthotic shoes in a pediatric patient
360	Prenatal psychological stress and the risk of atopic dermatitis in offspring: a longitudinal birth cohort study
367	Association between urinary phenols and parabens with pruritus and eczema
378	Almost half of pediatric patients with hidradenitis suppurativa diagnosis do not meet disease diagnostic criteria
379	Quality of life in children with ichthyosis
383	Doxycycline effects on the gut and skin microbiomes and lipidome in acne
388	A phase Ib trial in AD patients evaluating safety, tolerability, pharmacokinetics and efficacy of topical formulations containing the kappa-opioid receptor agonist WOL071-007
399	Blockade of the IL-12/IL-23 pathway with ustekinumab modulates the composition of the microbiome in lesional skin from psoriasis patients
405	Development of a scoring system for the prediction of the outcome of intravenous corticosteroid pulse therapy in rapidly-progressive alopecia areata
417	Immunotherapeutic options for skin cancer prevention in Xeroderma Pigmentosum
421	Is isotretinoin safe in patients with acne and inflammatory bowel disease?
425	Optimization of gentamicin therapy for recessive dystrophic epidermolysis bullosa patients harboring nonsense mutations.
427	Efficacy of the topical application of collagen-derived dipeptide and <i>Grifola frondosa</i> extract for treating atopic dermatitis
432	Investigating a causal relationship between body mass index and inflammatory skin disease using mendelian randomisation
438	Phase 2 trial of a neurokinin-1 receptor antagonist for the treatment of chronic Itch in epidermolysis bullosa patients
447	RASopathia comedo-like lesions induced by Vemurafenib : A model of skin lesions similar but not identical to those induced by dioxins (MADISH)
460	Non-histaminergic itch mediators elevated in the skin of human scabies patients and a porcine model of scabies
463	Safety of trimethoprim-sulfamethoxazole for PJP prophylaxis in patients taking methotrexate for chronic inflammatory or autoimmune diseases
472	CARD14 variants in pityriasis rubra pilaris
475	Drug reaction with eosinophilia and systemic symptoms (DRESS): Cytotoxic proteins play a vital role
479	Positive effects of hydrogen-water bathing in patients of psoriasis and parapsoriasis en plaques
480	Atopic dermatitis is an IL-13/IL10 driven disease with high molecular heterogeneity compared to psoriasis
483	
489	Dupilumab efficacy in atopic dermatitis in four randomized phase 3 trials (LIBERTY AD SOLO 1&2, CHRONOS, CAFE)
493	Recapitulating the Ehlers-Danlos Syndrome skin phenotype in a novel xenograft model
496	RXI-109 treatment to reduce the formation of hypertrophic dermal scars

497	Primary cutaneous aspergillosis (PCA) at the site of a skin abrasion covered with cyanoacrylate skin protectant in a neonate
502	Cyclosporine Vs. IV Corticosteroids for the management of SJS/TEN
503	Tofacitinib for recalcitrant cutaneous dermatomyositis
506	Regulatory T cells, Tregs, are increased in multi-parameter flow cytometric profiling of T cell populations in psoriasis
510	Development and validation of a risk prediction model for serious infection in patients with psoriasis using the British Association of Dermatologists Biologic Interventions Register (BADBIR)
512	Persistent elevated serum lactate and mortality in Stevens Johnson syndrome and toxic epidermal necrolysis
519	A combination of re-exposure and active learning maximizes medical student satisfaction and long-term recognition of skin lesions
527	Psoriasis and diet: Evidence synthesis from the Medical Board of the National Psoriasis Foundation
529	The associations of depression and coping methods on health-related quality of life for those with hidradenitis suppurativa
532	Patient-reported anxiety decreases with isotretinoin therapy
540	Intravenous immunoglobulin is an effective treatment for refractory cutaneous dermatomyositis
541	Digital assessment of hidradenitis suppurativa disease activity
543	Evaluating the burden of prior authorization in the treatment of psoriasis
545	What is your time worth? Comparison of distance travelled and waiting time between online and in-person care models from a randomized controlled trial
557	PROMIS pediatric sleep-wake function measures correlate with objective sleep disturbance in atopic dermatitis
562	Trends in scholarly productivity of US dermatology professors by academic status, degree, and gender
565	Fatigue in systemic lupus erythematosus and other autoimmune skin diseases
566	Acne core outcomes research network: Progress in core outcome set development in clinical trials
568	Evaluating results of an interferon- γ release assay in patients with autoimmune skin disease on hydroxychloroquine
585	Natural history of wound closure and other clinical endpoints in epidermolysis bullosa: Lessons from a 90-day multicenter trial
587	Results from the phase 3, double-blind, vehicle-controlled ESSENCE trial of the topical investigational drug SD-101 in epidermolysis bullosa
589	Use of electronic health record (EHR) tools and interactive didactics to empower pediatricians to manage atopic dermatitis (AD)
590	Utility of repeat latent tuberculosis screening in psoriasis patients treated with TNF-alpha inhibitors
596	Quality of care in dermatology: validation of novel provider-reported and patient-reported measures
598	Using the localized scleroderma cutaneous assessment tool to classify morphea by severity and identify clinically significant change in disease

599	Bringing therapeutic patient education in atopic dermatitis into the 21st century: a novel, low-cost, personalized, electronic health record-based framework
600	Improving Treatment of Acne Vulgaris by Primary Care Pediatricians
608	Compassionate Management of Potential Basal Cell Carcinoma in Pediatric Basal Cell Nevus Syndrome: A Case Series
613	Clinical application of cultured stratified epithelial sheets for stable vitiligo of children
622	Immature progenitor cells are enriched in psoriasis epidermis
623	Genome-wide DNA methylation profiling identifies differential methylation in uninvolved psoriatic epidermis
634	Skin ceramide profile in children with atopic dermatitis
648	The barrier abnormality of early-onset pediatric atopic dermatitis results from abnormalities in tight junctions and epidermal lipids, but not differentiation proteins
664	Atopic dermatitis: Linking skin barrier function with antioxidant defense
685	Necroptosis as special type of cell death in inflammatory skin diseases
689	The x-ray crystal structure of human keratin 1 with S233L mutation demonstrates mechanism of pathogenic tonotubular keratin formation leading to epidermolytic palmoplantar keratoderma
701	Imaging of the epidermal nerve dynamics and activity in the normal and pruritic dermatitis conditions
702	Age-dependent transformation of skin biomechanical properties and micromorphology during infancy and childhood
708	<i>PSORSIC2</i> is expressed in Hassall's bodies of the thymus and in terminally differentiated epidermal keratinocytes
714	Study of the cytotoxic effect of cleanser on human skin keratinocytes culture <i>in vitro</i> and correlation <i>in vivo</i>
719	Abnormalities in skin barrier status correlate with autism in a murine model: could assessments of skin barrier function assist in early diagnosis of autism?
735	Expanding the phenotypic spectrum of junctional epidermolysis bullosa with respiratory and renal involvement (JEB-RR)
736	Intravenous allogeneic mesenchymal stromal cell therapy in adults with recessive dystrophic epidermolysis bullosa is safe, improves quality of life and reduces itch
737	A novel missense mutation in exon 3 of the <i>TRPS1</i> gene in a patient with a mild phenotype of tricho-rhino-phalangeal syndrome type 1
740	Chromosomal microarray analysis for the molecular diagnosis of nevoid basal cell carcinoma syndrome and X-linked ichthyosis
741	Reduced microbial diversity is a feature of recessive dystrophic epidermolysis bullosa wounds
742	Identification of psoriasis-associated genes using genetically predicted transcriptomes
745	Filaggrin gene (<i>FLG</i>) promoter polymorphisms are associated with atopic dermatitis but not ichthyosis vulgaris in Japan
747	Intragenic copy number variation and Filaggrin variation are associated with Atopic Dermatitis in African Americans
748	Segmental odonto-maxillary dysplasia is caused by mosaic variants in the gene encoding beta-actin

750	Hematologic abnormalities in trichothiodystrophy
751	Gentamicin induces premature termination codon readthrough and restores laminin 332 in junctional epidermolysis bullosa harboring nonsense mutations
753	Use of hierarchical clustering and principal component analysis for deep phenotyping of patients with mutations in <i>XPD (ERCC2)</i> : trichothiodystrophy (TTD), xeroderma pigmentosum (XP) and XP/TTD
757	MiRNA signature in atopic dermatitis
758	Autoantibodies in epidermolysis bullosa
759	Successful <i>in vivo</i> COL7A1 gene delivery and correction of recessive dystrophic epidermolysis bullosa (RDEB) skin using an off the shelf HSV-1 vector (KB103)
760	<i>Ex-vivo</i> nonlinear microscopy imaging of Ehlers-Danlos syndrome-affected skin
766	The phenotypic spectrum of vascular anomalies associated with postzygotic mosaic variants in G-proteins.
767	Mechanisms contributing to the skin phenotype of ectodermal dysplasias caused by TP63 mutations
769	Filaggrin 2 deficiency causes generalized peeling of the skin
772	Development of a zebrafish model for CARD14-associated human disorders
773	Striate palmoplantar keratoderma resulting from a missense mutation in DSG1
775	A new phenotype combining hidradenitis suppurativa with Dowling-Degos disease caused by a founder mutation in PSENEN
777	SAM syndrome is characterized by extensive phenotype heterogeneity
778	A unique mixture of botanical extracts attenuates keratinocyte inflammation associated with atopic dermatitis
780	Rare genetic mutations contribute to alopecia areata etiology and provide rationale for sequencing patient genomes
782	Detection of mosaic copy-number variation from whole-exome sequencing in mosaic cutaneous disorders using XHMM and custom SNP approach
783	Molecular diagnosis of mosaic skin development disorders using next generation sequencing
792	Genomic tools identify overlapping Mendelian disorders and provide rationale for treatment of a patient with concurrent acrodermatitis enteropathica and epidermolysis bullosa
793	Genome-wide single nucleotide polymorphism-based autozygosity mapping facilitates identification of mutations in consanguineous families with epidermolysis bullosa
794	Postzygotic dominant-negative mutations of RHOA cause a mosaic neuroectodermal syndrome
796	Next generation sequencing identifies double homozygous mutations in two distinct genes (<i>EXPH5</i> and <i>COL17A1</i>) associated with different subtypes of epidermolysis bullosa
798	Biallelic COL7A1 editing in iPSCs via CRISPR/Cas9 for recessive dystrophic epidermolysis bullosa mutations
801	Identification of novel and recurrent <i>AAGAB</i> mutations in two patients with punctate palmoplantar keratoderma

803	A missense mutation in <i>KRT6A</i> located at coil 2B domain outside of helix termination motif leads to mild phenotype of pachyonychia congenita type 1
806	A circulus vitiosus causes loss of proteostasis in Cockayne syndrome
807	Revertant mosaicism in the first case of recessive epidermolysis bullosa simplex caused by <i>KRT5</i> mutations
808	Ex vivo COL7A1 correction for Recessive Dystrophic Epidermolysis Bullosa using CRISPR/Cas9 and Homology Directed Repair
809	Intradermal injection of bone marrow-MSC corrects Recessive Dystrophic Epidermolysis Bullosa in a xenograft model
810	A novel <i>KITLG</i> mutation detected only in the lesion of linear and whorled nevoid hypermelanosis
811	Cardiomyopathy in epidermolysis bullosa simplex patients with mutations in <i>KLHL24</i> gene
812	Type VII collagen and Nesprin 2, LINCing the basement membrane to altered cell cycle and increased DNA damage
814	Uniparental inheritance of junctional epidermolysis bullosa (JEB) through mutation of <i>ITGA6</i> and trisomic rescue
815	Genetic architecture of linear localized scleroderma
818	Multigene next-generation sequencing panel identifies a spectrum of mutations in patients with PXE
830	Fabry rat skin findings demonstrate potential roles of inflammation and lipotrophy in Fabry disease
833	A genome-wide association study identifies novel loci associated with severe acne and implicates hair follicle development in acne molecular pathogenesis
836	Non-viral gene therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB) using a highly branched poly(β -amino ester) polymer (HPAE-EB)
837	Genome-wide association study identifies three novel susceptibility loci for systemic lupus erythematosus in Han Chinese
838	Fine-mapping analysis of the HLA region for vitiligo in Chinese Han population
868	Hypoxia induced Cyr61 productions involved in the pathogenesis of infantile hemangioma
892	Atopic dermatitis endotypes based on allergen sensitization, <i>staphylococcus</i> reactivity, and underlying systemic inflammation
908	Histopathologic patterns in maculopapular drug eruptions and relation with systemic involvement
913	Caspase-1 regulates IL-33 secretion and partly mediates the development of atopic dermatitis-like inflammation in mice overexpressing IL-33 in the skin
914	<i>Cutibacterium acnes</i> phylotypes diversity loss: A trigger for skin inflammation process
915	Characterization of eicosanoid species altered in psoriatic skin
918	Candidalysin, a virulence factor of <i>Candida albicans</i> , activates human keratinocytes through MAPK and NF- κ B pathways
919	Successful treatment of psoriatic inflammation restores hyperglycemia
928	The loss of Langerhans cells in the pellagra skin lesion is preceded by the downregulation of CCR2 chemokine signaling

929	TH2 and TH17 cell differentiation is differentially regulated by innate anti-viral protein Trim32
934	Carbamazepine-10,11-epoxide drives CD8+ T-cell skin trafficking through NLRP3 inflammasome upregulation and contributes to necroptosis of keratinocytes in severe cutaneous adverse drug reactions
941	Molecular, physiological, and pathological backgrounds of recently proposed three subspecies of <i>Propionibacterium acnes</i>
944	A journey into psoriasis: From the adipose tissue to the skin
946	STAT3 deficiency in keratinocytes promotes serum IgE production in response to <i>Staphylococcus aureus</i> epicutaneous exposure
948	Microbiome of hidradenitis suppurativa
949	Skin microbiota alterations induce dysregulated IL-1 α responses that drive atopic dermatitis-like skin inflammation
950	Severity of pediatric atopic dermatitis correlates to hemolytic potential of <i>S. aureus</i> isolates from atopic lesions
951	Serum leucine-rich- α -2 glycoprotein is a biomarker for the effectiveness of biologic therapies in psoriasis
956	Psoriatic keratinocyte-derived exosomes with enriched proteasome subunits promote neutrophil activation and psoriasis development
957	TNF α - and IL-17A-mediated induction of IL-36 cytokines in human keratinocytes
958	The effect of Hsp90 inhibition on TNF α - and IL-17A-mediated signaling
962	Development of a novel humanized mouse model for atopic dermatitis
966	The human cutaneous microbiome composition changes after coal tar treatment of both healthy and atopic dermatitis skin
968	IL-36 γ is a strong inducer of IL-23A expression in human 3D psoriasis skin models consisting of lesional epidermal keratinocytes and dermal fibroblasts
969	ATP from human keratinocytes by mechanical stretching is one of the causes of Koebner phenomenon
979	Quantitative skin microbiome analysis identified new microbial species associated with atopic dermatitis
980	Oral tolerance induction in murine model of food allergy caused by epicutaneous sensitization
984	Superoxide dismutase 3 controls Th2 cytokine-mediated allergic inflammation through inhibition of periostin
985	Genome wide mapping identifies regulation of MAPKinase pathway as key genetic determinant of allergic contact dermatitis
989	Oral administration of <i>Lactococcus lactis</i> JCM 5805 activates skin immunity and ameliorates skin inflammation caused by <i>Staphylococcus aureus</i> infection
991	Comparative study of the skin lesions of Nakajo-Nishimura syndrome and <i>PSMB9</i> -related autoinflammatory syndrome with cutaneous adverse reactions by a proteasome inhibitor
992	The acne microbiome response to isotretinoin therapy
993	CARD14 gain-of-function mutation alone is sufficient to drive IL-23/IL-17-mediated psoriasiform skin inflammation <i>in vivo</i>
999	Prebiotic colloidal oatmeal supports the growth of <i>S. epidermidis</i> and enhances the

	production of lactic acid
1001	Mast cells and microvasculature network expansion in asymptomatic atopic dermatitis
1010	Nummular eczema is a distinct clinical entity with overlapping features of both, psoriasis and atopic eczema
1014	The Balanopreputial Microbiome in Male Genital Lichen Sclerosus
1015	Effect of an emollient on the skin fungal microbiome of atopic dermatitis (AD) patients
1016	Lysis by bacteriophages can modulate <i>Cutibacterium</i> (formerly <i>Propionibacterium</i>) <i>acnes</i> -induced immune responses
1017	Natural killer cell dysregulation underlies atopic dermatitis
1018	Neutrophil extracellular traps and type 1 IFN contribute to autoimmunity in Hidradenitis Suppurativa
1019	Lack of skin mast cell activation and sphingosine-1-phosphate elevation in male mice may explain gender disparity observed in pre-symptomatic atopic dermatitis
1022	Identification of mycobacteria species in skin tissue using amplification and melt curve analysis of the <i>hsp65</i> -gene
1023	Distinct <i>Cutibacterium acnes</i> strains isolated from lesional and non-lesional regions of acne promote differential immune responses
1039	Skin microbiome profiles of atopic dermatitis patients segregate into two community composition types that are stable before and after therapy
1045	Efficacy of a topical agent containing a naturally occurring lipid for alleviating drug resistant impetigo
1046	Molecular characterisation of a multidrug-resistant dermatophyte strain from a clinical non-responder and development of a potential therapy
1048	Treatment of nodulocystic acne with once weekly finasteride: A pilot study
1053	Systemic silver absorption following application of silver-based dressings to patients with Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis
1061	The safety of topical cannabidiol (CBD) for the treatment of acne
1083	Effect of RVT-502 therapy in the NC/Nga mouse model of atopic dermatitis
1084	PR022 inhibits IL-1 β <i>in vitro</i> and in a model of dermal hypersensitivity indicating potential efficacy for treatment of psoriasis and acne vulgaris
1088	Efficacy of AD-DER emollient in an <i>in vitro</i> atopic dermatitis model
1092	Mechanism of action of Oligofructans from <i>Ophiopogon japonicus</i> to treat atopic dermatitis
1093	Selective protection against bacterial adhesion by a natural second-skin film: maintenance of <i>S. epidermidis</i> / <i>S. aureus</i> balance
1094	Clinical pharmacokinetics and immunogenicity of GBR 830, a first-in-class humanized monoclonal antibody inhibiting OX40 to treat atopic dermatitis
1096	Non-invasive tape sampling reveals a type I interferon RNA signature in cutaneous lupus erythematosus that distinguishes affected from unaffected and healthy volunteer skin
1097	Small molecule Wnt pathway inhibitor (SM0755) as a potential topical treatment for psoriasis
1102	Phosphatidylglycerol as a potential therapy for psoriasis

1106	Successful Treatment of Periocular Discoid Lupus With Cyclosporine Ophthalmic Emulsion (Restasis)
1108	Preclinical evaluation of a novel fluoroquinolone for its multi-dimensional therapeutic effects against drug-resistant <i>Propionibacterium acnes</i> induced acne
1125	A wearable, flexible, conformable and depth-modulated phototherapy device: Initial application in morphea
1133	System for measuring UV protection index
1197	Folic acid protects melanocyte against the increased homocysteine induced apoptosis in vitiligo
1205	Vitiligo lesional and non-lesional skin shows polar cytokine activation
1221	Intracellular vacuoles observed in cultured melanocytes obtained from normally pigmented skin of a vitiligo patient were vanished by the treatment of anti-oxidants
1223	Multiple <i>MC1R</i> variants associated with extensive freckles and red hair found in a Mongolian family
1248	CO2 fractional laser for the treatment of small and medium congenital melanocytic nevi
1249	The treatment of acral vitiligo with autologous cultured epidermal grafts
1251	Janus kinase inhibitor tofacitinib does not facilitate the repigmentation in mice model of rhododendrol-induced leukoderma
1268	Necroptosis is a novel way of melanocyte death in oxidative-related vitiligo pathogenesis
1278	Targeting IL-15 signaling with an anti-CD122 antibody durably reverses vitiligo
1280	The role of surgery in hidradenitis suppurativa management
1283	Somatic GNAQ mutation in different structures of Port-wine Macrocheilia
1290	Despite abnormal vitamin D receptor expression in keloid scars, keloid keratinocytes can respond to vitamin D treatment in vitro
1294	Pediatric Atopic Dermatitis: A pilot comparative study across different races and ethnicities
1311	Efficacy of topical tofacitinib in promoting hair growth in non-scarring alopecia
1315	An Integrated model of alopecia areata biomarkers highlights both Th1/Th2 upregulation, with stronger correlations between Th2 activation and disease severity
1318	Both lesional and non-lesional skin from acne patients shows robust IL-17-skewing and upregulation of antimicrobial peptides
1320	Orchestrated cytotoxic and skin migratory ability lacking self-tolerance: circulating $\gamma\delta$ T-cells may promote alopecia areata
1343	Altered metabolism of elastic fibers and collagen fibers derived from TGF- β 1 mediated inflammation in atrophic acne scarring
1353	Inhibition of sebocyte HDAC activity promotes cytokine expression: An epigenetic model for acne pathogenesis by <i>Propionibacterium acnes</i>
1385	Dual mechanism of Type VII collagen transfer by bone marrow mesenchymal stem cell extracellular vesicles to recessive dystrophic epidermolysis bullosa fibroblasts
1411	The potential of adipose-derived stem cells for the treatment of recessive dystrophic epidermolysis bullosa
1446	Atopic Cytokines IL4/13 Perturb iPSC-Derived Itch-Specific Sensory Neurons

1468	BPM31510 improves wound healing and skin integrity in epidermolysis bullosa patients
1473	TRAF4 represses p53 signaling in keloid pathogenesis